THRIVE ACTIVITIES AT EASL LIVER CANCER SUMMIT 2026
The overall aim of the THRIVE project is to improve the outcome of both paediatric and adult liver cancer patients by understanding at-risk populations, tumour-host molecular interactions, developing biomarkers for current therapies and identify novel and affordable and societally-accepted treatments to overcome resistance.
Come to visit the THRIVE Stand in the exhibition area, serving as a point of interaction and networking for consortium partners and other stakeholders, and attend the upcoming THRIVE sessions in the scientific programme below:
- Single-cell Spatial transcriptomics of advanced HCC identifies association of CD8+ T-pure clusters with response and TREM2+-macrophage pure clusters with resistance to atezolizumab+bevacizumab (Ref. OS-2); Thursday, 22 Jan, 16:20 – 16:30 CEST;📍Plenary
- Cancer-associated fibroblasts in hepatocellular carcinoma tumor microenvironment and prediction of resistance to atezolizumab + bevacizumab treatment (Ref. PT-1-YI); Thursday, 22 Jan, 15:05 – 15:10 CEST;📍Moffat
- Serum Procalcitonin: A new tumor biomarker for the diagnosis and monitoring of fibrolamellar hepatocellular carcinoma (Ref. PT-2); Friday, 23 Jan, 15:25 – 15:30 CEST;📍Moffat
- Degradome implications in childhood liver cancer: Identifying CAND1 as a NEDDylation-regulated target in Hepatoblastoma (Ref. PO1-01-YI); Thursday, 22 Jan, 13:35 – 13:35 CEST;📍ePoster Area
GENIAL ACTIVITIES AT EASL LIVER CANCER SUMMIT 2026
The GENIAL project is dedicated to enhancing our understanding of the early stages of alcohol-related hepatocellular carcinoma (ALD-HCC) by integrating clinical hepatology expertise with artificial intelligence (AI). This innovative initiative, aims to significantly improve the diagnosis, prevention, and treatment of ALD-HCC.
Come to visit the GENIAL Stand in the exhibition area, serving as a point of interaction and networking for consortium partners.
